About Dendreon
Dendreon is a company based in Seal Beach (United States) founded in 1992 was acquired by Nanjing Xinbai in May 2018. It operates as a HealthTech and Professional Services. Dendreon has raised $21.7 million across 3 funding rounds from investors including New York Life Insurance, Nanjing Xinbai and Healthcare Ventures. Dendreon offers products and services including Provenge and Cellular Therapy Manufacturing. Dendreon operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seal Beach, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dendreon Pharmaceuticals Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.7 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Series C
Oct 22, 1999
-
Investors
New York Life Insurance
& 6 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dendreon
Dendreon offers a comprehensive portfolio of products and services, including Provenge and Cellular Therapy Manufacturing.
Provenge is used for advanced prostate cancer treatment.
Manufacturing support is provided for cellular therapy development.
People of Dendreon
Unlock access to complete
Software Development Team
28 people
Operations Team
20 people
Sales and Marketing
8 people
Leadership Team
5 people
Corporate Team
5 people
Finance and Accounting
5 people
Senior Team
4 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Dendreon
Dendreon has successfully raised a total of $21.7M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $10 million completed in October 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dendreon
Dendreon has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include New York Life Insurance, Nanjing Xinbai and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Biomedical investment financing and active management services.
|
Locked | Locked | Locked | |
|
Private equity investments are backed by a single-family office firm.
|
Locked | Locked | Locked |
Investor details for Dendreon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dendreon
Investment portfolio details for Dendreon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dendreon
Detailed financials for Dendreon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dendreon Comparisons
Peer comparison for Dendreon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dendreon
Dendreon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Dendreon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dendreon
Complete news archive for Dendreon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dendreon
Dendreon was founded in 1992 and raised its 1st funding round 4 years after it was founded.
Dendreon is headquartered in Seal Beach, United States. It is registered at Seal Beach, California, United States.
Dendreon is a funded company, having raised a total of $21.7M across 3 funding rounds to date.
Dendreon is engaged in the development and delivery of cellular therapies and immunotherapies aimed at improving patient outcomes. The company operates within the healthcare sector, specializing in biotechnology with a focus on innovative treatments like Provenge, an FDA-approved immunotherapy for prostate cancer. Strategic partnerships and research are leveraged to advance complex cell therapies. Manufacturing services are also provided to support other companies in bringing life-saving innovations to market.
Dendreon's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Dendreon offers Provenge and Cellular Therapy Manufacturing.
Dendreon has 7 investors. Key investors include New York Life Insurance, Nanjing Xinbai, Healthcare Ventures, Sanderling Ventures, and Vulcan Capital.